ジョンソン & Johnson vaccine less effective against Delta variant: 調査

The results of the 調査 were published by bioRxiv but have yet to be peer-reviewed or published in any scientific journal.

A registered nurse fills a syringe with the Johnson &アンプ; Johnson COVID-19 vaccine at a pop up vaccination site in the Staten Island borough of New York.

A registered nurse fills a syringe with the Johnson &アンプ; Johnson COVID-19 vaccine at a pop up vaccination site in the Staten Island borough of New York. (AP)

研究によると, the mRNA-based vaccines Pfizer and Moderna were 94 に 95% effective in preventing COVID-19 whereas theadenoviral vector-based” ジョンソン & Johnson had a roughly 67% effective rate.

The study was led Nathaniel Landau, a virologist at New York University’s Grossman School of Medicine. Landau told ニューヨークタイムズ that the aim of the study wasn’t to dissuade people from getting the J&J vaccine.

CDC: DELTA VARIANT ACCOUNTS FOR 83% OF US CASES

“[W]e hope that in the future, it will be boosted with either another dose of J&J or a boost with Pfizer or Moderna,” Landau said.

Fox Newsに提供された声明の中で, ジョンソン & Johnson cited previous studies which showed that a single-shot of its COVID-19 vaccine was 85% ワクチン “at protecting against severe disease and provided complete protection against hospitalization and death.

The company said Landau’s study did not speak to the full nature of immune protection. It cited additional company data demonstrating that a Johnson & Johnson single-shot COVID-19 vaccinegenerated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.

コメントは締め切りました.